Insomnia is a common comorbidity among adolescents with migraine. This randomized controlled clinical trial aims to determine efficacy of cognitive-behavioral therapy (CBT) for insomnia, as well as the combined effect of CBT insomnia and pain interventions, on reducing insomnia symptoms and headache-related disability in adolescents with migraine. The long-term goal is to offer effective, tailored self-management interventions that can address migraine and co-morbid sleep problems in adolescence and disrupt a cycle of persistent, disabling migraine from continuing into adulthood.
This aims of this study are to: 1) test efficacy of cognitive-behavioral therapy (CBT) insomnia intervention for youth with migraine and comorbid insomnia, and 2) investigate how changes in sleep may modify response to CBT pain intervention. Participants will include 250 youth and their parents. Youth will be ages 11-17 years, with migraine (with or without aura, chronic migraine) and comorbid insomnia. In Phase 1, participants will be randomly assigned to receive access to internet-delivered CBT insomnia intervention or internet-delivered sleep education control over 6 weeks. In Phase 2, all participants will receive access to internet-delivered CBT pain intervention over 6 weeks. Assessments will occur at baseline, immediately after Phase 1 intervention, immediately after Phase 2 intervention, and 6 month follow-up.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
224
The program delivers the core components of CBT for insomnia including sleep hygiene, stimulus control, and sleep restriction. Treatment duration is 6 weeks.
The program delivers the core components of CBT for pain management including: pain education, training in behavioral and cognitive pain coping skills, instruction in increasing activity participation, and training in parental operant and communication strategies. Treatment duration is 6 weeks.
The program delivers publicly available information about sleep.
Seattle Children's Hospital
Seattle, Washington, United States
Change in insomnia symptoms
The 7-item Insomnia Severity Index (ISI) measures severity of insomnia symptoms. Total scores above 8 on the ISI indicate clinically significant insomnia in adult and adolescent samples.
Time frame: Baseline, immediately after treatment phase 1, immediately after treatment phase 2, 6-month follow-up
Change in headache-related disability
The CALI-9 is a 9-item self-report instrument of headache-related disability in children and adolescents that measures difficulty in performing usual daily physical, social, and recreational activities. The measure will be completed daily for 14 days at baseline, after phase 1, after phase 2, and 6-month follow-up
Time frame: Baseline, immediately after treatment phase 1, immediately after treatment phase 2, 6-month follow-up
Change in sleep quality
The Adolescent Sleep Wake Scale-Short Form (ASWS) is a 10-item measure. The total score indicates overall perception of sleep quality.
Time frame: Baseline, immediately after treatment phase 1, immediately after treatment phase 2, 6-month follow-up
Change in sleep patterns
14-days of actigraphic monitoring with the Actiwatch Spectrum Plus to assess minutes of estimated sleep, wake time after sleep onset, and sleep efficiency.
Time frame: Baseline, immediately after treatment phase 1, immediately after treatment phase 2, 6-month follow-up
Change in headache frequency
The number of headache days reported each day for 14 days.
Time frame: Baseline, immediately after treatment phase 1, immediately after treatment phase 2, 6-month follow-up
Change in headache pain intensity
11-point numerical rating scale with anchors of 0 = no pain to 10 = worst pain possible. Reported each day for 14 days.
Time frame: Baseline, immediately after treatment phase 1, immediately after treatment phase 2, 6-month follow-up
Change in anxiety symptoms
The Generalized Anxiety Disorder-7 is a 7-item measure. The total score indicates anxiety severity over the last two weeks.
Time frame: Baseline, immediately after treatment phase 1, immediately after treatment phase 2, 6-month follow-up
Change in depressive symptoms
The Patient Health Questionnaire-9 is a 9 item measure. The total score indicates severity of depression over the last two weeks.
Time frame: Baseline, immediately after treatment phase 1, immediately after treatment phase 2, 6-month follow-up
Change in health-related quality of life as assessed by the Pediatric Quality of Life Inventory 4.0
The Pediatric Quality of Life Inventory 4.0. is a measure of health-related quality of life. The total score indicates perceived mental and physical health.
Time frame: Baseline, immediately after treatment phase 1, immediately after treatment phase 2, 6-month follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.